Physician profile
Jesse Corbello
NPI 1063602449
$1,338.74
in general payments reported to CMS, 2019-2025
21 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $151 · 2022: $165 · 2023: $317 · 2024: $203 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $179.61 | 2022-2023 | Nxstage System One, Liberty Select Cycler |
| Astrazeneca Pharmaceuticals LP | $174.71 | 2020-2023 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $148.84 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $137.41 | 2020 | |
| Akebia Therapeutics INC | $104.35 | 2021-2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $89.11 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.95 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.09 | 2023-2025 | |
| Amgen INC. | $50.50 | 2023-2025 | Tavneos |
| Ardelyx, INC. | $43.79 | 2025 | Ibsrela |
| Lilly USA, LLC | $40.38 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $38.67 | 2023-2025 | Jynarque |
| Glaxosmithkline, LLC. | $38.31 | 2022-2025 | Arexvy, Shingrix |
| Shield Therapeutics INC | $32.49 | 2025 | |
| Aurinia Pharma U.S., INC. | $26.73 | 2023 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.74 | 2021 | |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Mallinckrodt Hospital Products INC. | $18.56 | 2022 | |
| Fresenius USA Marketing, INC. | $18.12 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.64 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Corbello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.